Exelixis (EXEL) Competitors

$49.64 -1.46 (-2.85%)

As of 01:14 PM Eastern

EXEL vs. ALNY, BIIB, UTHR, INCY, and NBIX

Should you buy Exelixis stock or one of its competitors? MarketBeat compares Exelixis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exelixis include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does Exelixis compare to Alnylam Pharmaceuticals?

Exelixis (NASDAQ:EXEL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Exelixis currently has a consensus price target of $47.35, suggesting a potential downside of 4.61%. Alnylam Pharmaceuticals has a consensus price target of $471.96, suggesting a potential upside of 63.27%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.81

Exelixis has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

Exelixis has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Exelixis is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.38	$782.57M	$3.01	16.49
Alnylam Pharmaceuticals	$3.71B	10.39	$313.75M	$3.66	78.98

Exelixis has a net margin of 35.08% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

In the previous week, Exelixis had 10 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 20 mentions for Exelixis and 10 mentions for Alnylam Pharmaceuticals. Exelixis' average media sentiment score of 0.75 beat Alnylam Pharmaceuticals' score of 0.44 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

85.3% of Exelixis shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats Exelixis on 9 of the 16 factors compared between the two stocks.

How does Exelixis compare to Biogen?

Exelixis (NASDAQ:EXEL) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Exelixis has a net margin of 35.08% compared to Biogen's net margin of 13.81%. Exelixis' return on equity of 39.89% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Biogen	13.81%	12.83%	8.01%

In the previous week, Biogen had 31 more articles in the media than Exelixis. MarketBeat recorded 51 mentions for Biogen and 20 mentions for Exelixis. Biogen's average media sentiment score of 0.94 beat Exelixis' score of 0.75 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	21 Very Positive mention(s)	12 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Exelixis has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Biogen has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

Exelixis presently has a consensus target price of $47.35, suggesting a potential downside of 4.61%. Biogen has a consensus target price of $215.62, suggesting a potential upside of 12.52%. Given Biogen's stronger consensus rating and higher probable upside, analysts clearly believe Biogen is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39
Biogen	1 Sell rating(s)	13 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.52

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.38	$782.57M	$3.01	16.49
Biogen	$9.89B	2.86	$1.29B	$9.32	20.56

Summary

Biogen beats Exelixis on 10 of the 16 factors compared between the two stocks.

How does Exelixis compare to United Therapeutics?

Exelixis (NASDAQ:EXEL) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

United Therapeutics has a net margin of 40.62% compared to Exelixis' net margin of 35.08%. Exelixis' return on equity of 39.89% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
United Therapeutics	40.62%	19.24%	17.25%

In the previous week, United Therapeutics had 9 more articles in the media than Exelixis. MarketBeat recorded 29 mentions for United Therapeutics and 20 mentions for Exelixis. Exelixis' average media sentiment score of 0.75 beat United Therapeutics' score of 0.58 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	13 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Exelixis has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Exelixis presently has a consensus target price of $47.35, suggesting a potential downside of 4.61%. United Therapeutics has a consensus target price of $619.42, suggesting a potential upside of 8.78%. Given United Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe United Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.38	$782.57M	$3.01	16.49
United Therapeutics	$3.18B	7.59	$1.33B	$27.09	21.02

Summary

United Therapeutics beats Exelixis on 13 of the 17 factors compared between the two stocks.

How does Exelixis compare to Incyte?

Exelixis (NASDAQ:EXEL) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

Incyte has higher revenue and earnings than Exelixis. Incyte is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.38	$782.57M	$3.01	16.49
Incyte	$5.14B	3.70	$1.29B	$7.08	13.44

Exelixis currently has a consensus target price of $47.35, suggesting a potential downside of 4.61%. Incyte has a consensus target price of $104.26, suggesting a potential upside of 9.61%. Given Incyte's stronger consensus rating and higher possible upside, analysts plainly believe Incyte is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39
Incyte	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

Exelixis has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Incyte has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

In the previous week, Exelixis had 10 more articles in the media than Incyte. MarketBeat recorded 20 mentions for Exelixis and 10 mentions for Incyte. Incyte's average media sentiment score of 0.92 beat Exelixis' score of 0.75 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a net margin of 35.08% compared to Incyte's net margin of 26.71%. Exelixis' return on equity of 39.89% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Incyte	26.71%	26.66%	19.77%

85.3% of Exelixis shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 16.2% of Incyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Incyte beats Exelixis on 10 of the 17 factors compared between the two stocks.

How does Exelixis compare to Neurocrine Biosciences?

Exelixis (NASDAQ:EXEL) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Exelixis has higher earnings, but lower revenue than Neurocrine Biosciences. Exelixis is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.38	$782.57M	$3.01	16.49
Neurocrine Biosciences	$2.86B	5.53	$478.60M	$6.49	24.25

Exelixis presently has a consensus price target of $47.35, suggesting a potential downside of 4.61%. Neurocrine Biosciences has a consensus price target of $184.15, suggesting a potential upside of 16.99%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.82

Exelixis has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

In the previous week, Exelixis had 7 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 20 mentions for Exelixis and 13 mentions for Neurocrine Biosciences. Exelixis' average media sentiment score of 0.75 beat Neurocrine Biosciences' score of 0.52 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a net margin of 35.08% compared to Neurocrine Biosciences' net margin of 21.55%. Exelixis' return on equity of 39.89% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Neurocrine Biosciences	21.55%	19.79%	13.82%

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Neurocrine Biosciences beats Exelixis on 9 of the 16 factors compared between the two stocks.

Get Exelixis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXEL vs. The Competition

Export

Metric	Exelixis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.49B	$3.33B	$6.24B	$12.30B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	16.50	18.15	20.39	25.31
Price / Sales	5.38	280.54	541.96	72.69
Price / Cash	16.94	125.29	43.26	56.33
Price / Book	6.45	6.67	9.79	6.90
Net Income	$782.57M	$24.11M	$3.56B	$333.98M
7 Day Performance	3.08%	3.81%	0.43%	-0.27%
1 Month Performance	12.11%	-3.19%	-0.87%	1.56%
1 Year Performance	7.31%	68.06%	35.95%	32.45%

Exelixis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXEL Exelixis	2.7035 of 5 stars	$49.64 -2.9%	$47.35 -4.6%	+14.4%	$12.49B	$2.32B	16.50	1,077
ALNY Alnylam Pharmaceuticals	4.4095 of 5 stars	$301.11 +1.1%	$471.96 +56.7%	+9.7%	$40.18B	$4.29B	82.27	2,770
BIIB Biogen	3.7588 of 5 stars	$189.13 +1.0%	$214.23 +13.3%	+59.0%	$27.92B	$9.94B	20.29	7,500	Trending News Analyst Forecast
UTHR United Therapeutics	3.7322 of 5 stars	$572.20 -1.6%	$601.50 +5.1%	+92.1%	$25.08B	$3.18B	20.51	1,400	Insider Trade Analyst Revision
INCY Incyte	4.2852 of 5 stars	$97.47 +0.3%	$104.26 +7.0%	+59.6%	$19.47B	$5.36B	13.77	2,844

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXEL) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exelixis (EXEL) Competitors

EXEL vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Exelixis compare to Alnylam Pharmaceuticals?

Summary

How does Exelixis compare to Biogen?

Summary

How does Exelixis compare to United Therapeutics?

Summary

How does Exelixis compare to Incyte?

Summary

How does Exelixis compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exelixis (EXEL) Competitors

EXEL vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Exelixis compare to Alnylam Pharmaceuticals?

Do analysts prefer EXEL or ALNY?

Which has more risk and volatility, EXEL or ALNY?

Which has preferable earnings and valuation, EXEL or ALNY?

Is EXEL or ALNY more profitable?

Does the media refer more to EXEL or ALNY?

Do insiders & institutionals have more ownership in EXEL or ALNY?

Summary

How does Exelixis compare to Biogen?

Is EXEL or BIIB more profitable?

Does the media refer more to EXEL or BIIB?

Do institutionals & insiders have more ownership in EXEL or BIIB?

Which has more volatility & risk, EXEL or BIIB?

Do analysts prefer EXEL or BIIB?

Which has higher valuation & earnings, EXEL or BIIB?

Summary

How does Exelixis compare to United Therapeutics?

Is EXEL or UTHR more profitable?

Does the media refer more to EXEL or UTHR?

Do institutionals & insiders have more ownership in EXEL or UTHR?

Which has more volatility & risk, EXEL or UTHR?

Do analysts prefer EXEL or UTHR?

Which has higher valuation & earnings, EXEL or UTHR?

Summary

How does Exelixis compare to Incyte?

Which has preferable valuation & earnings, EXEL or INCY?

Do analysts recommend EXEL or INCY?

Which has more risk and volatility, EXEL or INCY?

Does the media refer more to EXEL or INCY?

Is EXEL or INCY more profitable?

Do insiders and institutionals have more ownership in EXEL or INCY?

Summary

How does Exelixis compare to Neurocrine Biosciences?

Which has preferable earnings & valuation, EXEL or NBIX?

Do analysts rate EXEL or NBIX?

Which has more volatility & risk, EXEL or NBIX?

Does the media favor EXEL or NBIX?

Is EXEL or NBIX more profitable?

Do insiders & institutionals have more ownership in EXEL or NBIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools